Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clazosentan (Actelion).

Dirk Uhlmann1

  • 1University of Leipzig, Germany. uhld@medizin.uni-leipzig.de

Current Opinion in Investigational Drugs (London, England : 2000)
|March 25, 2006
PubMed
Summary

Clazosentan, an endothelin ETA antagonist, may prevent brain damage after subarachnoid hemorrhage. Phase IIb clinical study results are anticipated in early 2006.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chondroma of the Sternum Growing in a Pregnant Patient: A Case Report.

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·2017
Same author

The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy.

BMC surgery·2016
Same author

Bilateral elastofibroma dorsi: a case report of an uncommon and under-diagnosed tumor.

Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery·2016
Same author

The value of liver resection for focal nodular hyperplasia: resection yes or no?

European journal of medical research·2015
Same author

Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.

Anticancer research·2014
Same author

Single-center experience using organs after rescue allocation for pancreas transplant in the eurotransplant region.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation·2014

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Subarachnoid hemorrhage (SAH) frequently leads to cerebral vasospasm, increasing the risk of cerebral infarction and ischemia.
  • Endothelin ETA receptor antagonists represent a potential therapeutic strategy to mitigate these complications.

Purpose of the Study:

  • To evaluate the efficacy and safety of clazosentan for the prevention of cerebral infarction and ischemia in patients following subarachnoid hemorrhage.

Main Methods:

  • A phase IIb/III clinical study was conducted.
  • Participants received clazosentan, an endothelin ETA antagonist.
  • The study assessed outcomes related to cerebral infarction and ischemia post-SAH.

Main Results:

  • Results from the phase IIb portion of the study are pending.
  • The study is evaluating clazosentan's potential to prevent neurological damage.

Conclusions:

  • Clazosentan is under investigation as a novel therapeutic agent for SAH complications.
  • Further results are needed to determine the clinical utility of clazosentan.

Related Experiment Videos